| ADAM 12 may be used to reduce the false positive rate of first trimester combined screening for Down syndrome. | |
| | |
MedLine Citation:
|
PMID: 20013872 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: ADAM12 has been shown to be an efficient maternal serum marker for Down syndrome (DS) in the first trimester; but recent studies, using a second generation assay, have not confirmed these findings. We examined the efficiency of a second generation assay for ADAM12. MATERIALS AND METHODS: ADAM12 concentrations were determined in 28 first trimester DS and 503 control pregnancies using a novel Research Delfia ADAM12 kit. Log10MoM distributions of ADAM12 and correlations with other markers were established. Population performance of screening was estimated by Monte Carlo simulation. RESULTS: ADAM12 was significantly reduced in the first trimester in DS pregnancies with a log10MoM of -0.1621 (equivalent to 0.68 MoM) (p < 0.001). The reduction decreased with advancing gestational age. ADAM12 used with PAPP-A + hCG beta + NT (CUB screening) increased the detection rate (DR) from 86% to 89% for a false positive rate (FPR) of 5%. When used for a fixed DR of 90%, the addition of ADAM12 resulted in a 25% reduction of the FPR. CONCLUSION: ADAM12 is a moderately effective DS marker. It is not a cost-effective addition to CUB screening, but may be used to reduce the FPR in selected high-risk cases. |
| | |
Authors:
|
Michael Christiansen; Kasper Pihl; Paula L Hedley; Anne-Cathrine Gjerris; Pia ? Lind; Severin Olesen Larsen; Lone Krebs; Torben Larsen |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: Prenatal diagnosis Volume: 30 ISSN: 1097-0223 ISO Abbreviation: Prenat. Diagn. Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-02-01 Completed Date: 2010-04-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8106540 Medline TA: Prenat Diagn Country: England |
Other Details:
|
Languages: eng Pagination: 110-4 Citation Subset: IM |
Copyright Information:
|
(c) 2009 John Wiley & Sons, Ltd. |
Affiliation:
|
Department of Clinical Biochemistry and Immunology, Statens Serum Institut, Copenhagen, Denmark. mic@ssi.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
ADAM Proteins
/
blood*,
diagnostic use Adult Biological Markers Case-Control Studies Down Syndrome / blood*, diagnosis* False Positive Reactions Female Humans Mass Screening Membrane Proteins / blood*, diagnostic use Pregnancy Pregnancy Trimester, First Prenatal Care |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Membrane Proteins; EC 3.4.24.-/ADAM 12 protein; EC 3.4.24.-/ADAM Proteins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Potential attractants for detecting and removing invading Gambian giant pouched rats (Cricetomys gam...
Next Document: Free leptin index and PAPP-A: a first trimester maternal serum screening test for pre-eclampsia.